{
  "variant": {
    "gene": "KRAS",
    "position": "chr12:25245350",
    "nucleotide_change": "c.35G>T",
    "protein_change": "p.G12V",
    "dbsnp_id": "rs121913529"
  },
  "structural_data": {
    "pdb_id": "6OIM",
    "protein": "KRAS GTPase (isoform A)",
    "affected_residue": 12,
    "wt_amino_acid": "Gly",
    "mut_amino_acid": "Val",
    "domain": "Switch I region",
    "location_detail": "N-terminal region critical for GTP/GDP binding and nucleotide exchange"
  },
  "structural_impact": {
    "steric_effect": "HIGH",
    "reason": "Glycine\u2192Valine substitution increases side-chain volume (~100 \u00c5\u00b3 expansion)",
    "consequence": "Altered conformational dynamics in Switch I/II regions affecting GTPase activity",
    "impact_on_gdp_binding": "Compromised GDP release; impaired GTPase-activating protein (GAP) interactions",
    "gtp_loading_state": "Shifted towards constitutive GTP-bound (active) state"
  },
  "functional_impact": {
    "classification": "Pathogenic/Activating Mutation",
    "mechanism": "Loss of GTPase intrinsic activity + impaired GAP-mediated GTP hydrolysis",
    "functional_consequence": "Constitutive KRAS activation",
    "downstream_signaling": [
      "Increased MAPK/ERK pathway activation",
      "Enhanced PI3K/AKT pathway signaling",
      "Elevated RalGDS activation",
      "Sustained mTORC1 signaling"
    ]
  },
  "cancer_association": {
    "disease": "Colorectal Cancer",
    "prevalence_in_crc": "40-45% of CRC harbor KRAS mutations",
    "g12_hotspot_frequency": "G12 is the most common KRAS mutation site in CRC",
    "g12v_frequency": "~7-10% of KRAS-mutant CRC",
    "clinical_significance": "Associated with worse prognosis and therapy resistance"
  },
  "therapeutic_implications": {
    "existing_drugs": [
      "KRAS G12C inhibitors (not applicable - G12V is different)",
      "MEK inhibitors (trametinib, selumetinib) - target downstream MAPK",
      "PI3K/AKT/mTOR inhibitors (multiple targets)"
    ],
    "emerging_approaches": [
      "KRAS G12V-specific inhibitors (in development)",
      "Allosteric KRAS inhibitors",
      "Combination therapies targeting multiple KRAS effector pathways"
    ],
    "resistance_mechanisms": "High frequency of secondary mutations affecting RAF, MEK, TP53"
  },
  "structural_stability_prediction": {
    "protein_fold_stability": "MAINTAINED",
    "mutation_type": "Conservative (hydrophobic\u2192hydrophobic)",
    "overall_structure": "Protein fold remains stable; local conformational changes in Switch regions",
    "thermodynamic_stability": "\u0394\u0394G \u2248 -1 to -2 kcal/mol (slight destabilization or neutral)"
  },
  "recommendation": "PATHOGENIC VARIANT - Functional driver mutation in CRC. Recommend targeted therapy strategies."
}